Holen Sie sich die Stockscreener-App
223.06
0.29%
-0.64
Vorhandelsmarkt:
224.00
0.94
+0.42%
Schlusskurs vom Vortag:
$223.70
Offen:
$226.1
24-Stunden-Volumen:
1.02M
Relative Volume:
1.48
Marktkapitalisierung:
$11.48B
Einnahmen:
$708.24M
Nettoeinkommen (Verlust:
$-188.30M
KGV:
-59.65
EPS:
-3.7392
Netto-Cashflow:
$-70.99M
1W Leistung:
+20.57%
1M Leistung:
+32.38%
6M Leistung:
+64.39%
1J Leistung:
+91.48%
1-Tages-Spanne:
$222.33
$231.00
1-Wochen-Bereich:
$180.00
$234.29
52-Wochen-Spanne:
$96.09
$234.29
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
223.06 | 11.48B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock - MarketBeat
Axsome Therapeutics COO Mark Jacobson sells $1.08m in stock - Investing.com
Axsome Therapeutics (AXSM) reports Q1 loss, beats revenue estimates - MSN
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales - Yahoo Finance UK
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock - Sahm
Axsome Therapeutics Reports Strong Q1 2026 Results Driven by Revenue Growth and FDA Approval for AUVELITY - IndexBox
Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00 - MarketBeat
Robert W. Baird Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho - MarketBeat
B. Riley Adjusts Price Target on Axsome Therapeutics to $300 From $230, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Axsome Therapeutics to $310 From $228, Maintains Outperform Rating - marketscreener.com
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS Group AG - MarketBeat
RBC Raises Price Target on Axsome Therapeutics to $302 From $242, Keeps Outperform Rating - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2026 Earnings Call Transcript - Insider Monkey
Axsome Therapeutics 1Q Rev $191.2M >AXSM - Moomoo
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Mizuho raises Axsome Therapeutics price target on Auvelity outlook - Investing.com
Mizuho raises Axsome Therapeutics price target on Auvelity outlook By Investing.com - Investing.com Canada
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression - Sahm
B.Riley raises Axsome Therapeutics price target on sales guidance - Investing.com
B.Riley raises Axsome Therapeutics price target on sales guidance By Investing.com - Investing.com Canada
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Axsome Therapeutics 1Q Auvelity Net Product Sales $153.2M, Up 59% >AXSM - Moomoo
Axsome Therapeutics Earnings Call Signals Aggressive Growth - TipRanks
RBC Capital raises Axsome stock price target on higher revenue outlook By Investing.com - Investing.com South Africa
Axsome Therapeutics Q1 2026 earnings preview - MSN
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - MSN
Baird raises Axsome Therapeutics stock price target on Auvelity launch By Investing.com - Investing.com Australia
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
Axsome Therapeutics, Inc. 1Q 2026: Revenue $191.2M, EPS $(1.26) — 10-Q Summary - TradingView
Baird raises Axsome Therapeutics stock price target on Auvelity launch - Investing.com
RBC Capital raises Axsome stock price target on higher revenue outlook - Investing.com
Oppenheimer raises Axsome Therapeutics price target on Auvelity sales By Investing.com - Investing.com Australia
Axsome Therapeutics Reports Wider Than Expected Q1 2026 Loss - AlphaStreet
Oppenheimer raises Axsome Therapeutics price target on Auvelity sales - Investing.com
Why Did Axsome Therapeutics Stock Hit Another Record High Today? - The Globe and Mail
Axsome Therapeutics Inc Stock (AXSM) Moved Up by 10.20% on May 4: Facts Behind the Movement - TradingKey
Guggenheim raises Axsome stock price target to $260 on drug sales - Investing.com
AXSM Stock Jumps As FDA Clears Auvelity For Alzheimer’s Agitation - StocksToTrade
Axsome Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Axsome Q1 2026 slides: 57% revenue growth amid FDA approval milestone - Investing.com India
Axsome Therapeutics: Current Cash Sufficient to Fund Anticipated Operations Into Cash Flow Positivity >AXSM - Moomoo
Axsome Therapeutics 1Q Loss/Shr $1.26 >AXSM - Moomoo
TD Cowen raises Axsome stock price target on strong Q1 results By Investing.com - Investing.com South Africa
TD Cowen raises Axsome stock price target on strong Q1 results - Investing.com
Axsome Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied (AXSM) - Seeking Alpha
Why is Axsome therapeutics trending amid Nasdaq Composite Index gains? - Kalkine Media
AXSM: Q1 revenue up 57% YoY, Auvelity FDA-approved for Alzheimer's agitation, peak sales outlook raised - TradingView
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Option Exercise |
12.95 |
233 |
3,017 |
233 |
| Jacobson Mark L. | Chief Operating Officer |
May 04 '26 |
Sale |
227.94 |
4,517 |
1,029,605 |
0 |
| Jacobson Mark L. | Chief Operating Officer |
May 05 '26 |
Sale |
228.18 |
233 |
53,166 |
0 |
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):